Joel Picus
- Oncology top 0.1%
- Pancreatic and Hepatic Oncology Research 30
- Colorectal Cancer Treatments and Studies 27
- Cancer Immunotherapy and Biomarkers 23
- Cancer Treatment and Pharmacology 21
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics 25
- Pulmonary and Respiratory Medicine top 0.05%
- Prostate Cancer Treatment and Research 51
- Renal cell carcinoma treatment 32
- Immunology top 1%
- Hepatology top 1%
-
- Bladder and Urothelial Cancer Treatments 29
- Co-authors
- Nicholas J. VogelzangSusan HalabiEric J. SmallNeal J. MeropolJorge A. GarcíaChristopher J. SweeneyGary A. KoretzkyNoah M. Hahn
- Partner nations
- United StatesCanadaFrance
In The Last Decade
Joel Picus
218 papers receiving 17.8k citations
Hit Papers
Peers
Comparison fields: 5 of 140
- Oncology 9.3k
- Cancer Research 4.6k
- Pulmonary and Respiratory Medicine 9.2k
- Immunology 2.2k
- Hepatology 771
Countries citing papers authored by Joel Picus
This map shows the geographic impact of Joel Picus's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Picus with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Picus more than expected).
Fields of papers citing papers by Joel Picus
This network shows the impact of papers produced by Joel Picus. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Picus. The network helps show where Joel Picus may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Joel Picus, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 4 | |
| 2 | 2024 | 4 | |
| 3 | 2023 | 2 | |
| 4 | 2023 | 31 | |
| 5 | 2021 | 18 | |
| 6 | 2021 | 9 | |
| 7 | 2020 | 5 | |
| 8 | 2019 | 31 | |
| 9 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trialbreakdown → | 2017 | 507 |
| 10 | 2017 | 12 | |
| 11 | 2016 | 311 | |
| 12 | 2014 | 80 | |
| 13 | 2012 | 64 | |
| 14 | Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) and Updated Overall Survival (OS) of Sunitinib versus Placebo for Patients with Progressive, Unresectable, Well Differentiated Pancreatic Neuroendocrine Tumor (NET) | 2012 | 4 |
| 15 | 2011 | 147 | |
| 16 | 2010 | 25 | |
| 17 | 2009 | 418 | |
| 18 | Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancerbreakdown → | 2008 | 1473 |
| 19 | 2006 | 33 | |
| 20 | 1985 | 14 |
About Joel Picus
Joel Picus is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 224 papers that have together received 18.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (51 papers), Renal cell carcinoma treatment (32 papers), Pancreatic and Hepatic Oncology Research (30 papers), Bladder and Urothelial Cancer Treatments (29 papers), Colorectal Cancer Treatments and Studies (27 papers), Cancer Genomics and Diagnostics (25 papers), Cancer Immunotherapy and Biomarkers (23 papers) and Cancer Treatment and Pharmacology (21 papers). The work is most often cited by research in Oncology (9.3k citations), Cancer Research (4.6k citations) and Pulmonary and Respiratory Medicine (9.2k citations). Joel Picus has collaborated with scholars based in United States, Canada and France. Frequent co-authors include Nicholas J. Vogelzang, Susan Halabi, Eric J. Small, Neal J. Meropol, Jorge A. García, Christopher J. Sweeney, Gary A. Koretzky, Noah M. Hahn, Robert Dreicer and Walter M. Stadler. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer, International Journal of Radiation Oncology*Biology*Physics and The Journal of Urology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.